Antibiotics Market by Class (Beta Lactam & Beta Lactamase, Quinolones, Macrolides, and Others), Drug Origin (Natural, Semisynthetic, and Synthetic), Spectrum of Activity (Broad-spectrum Antibiotic and Narrow-spectrum Antibiotic), and Route of Administration (Oral, Intravenous, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025
- Published Date: 2020-10-18
- Report ID: 3250
- Pages: 282
-
Format:
Antibiotics Market Overview :
The global antibiotics market generated $42,335 million in 2017, and is projected to reach $50,374 million by 2025, growing at a CAGR of 2.1% from 2018 to 2025.
Antibiotic is an antimicrobial substance, which are used in the treatment and prevention of bacterial infections, as well as used rarely to combat protozoan infections. Antibiotics are the medicines that either discontinue bacteria from growing or destroy bacteria straight referred as bacteriostatic and bactericidal antibiotics respectively. Easy accessibility of antibiotics at drug stores and in hospitals with prescription or without prescription fuels their consumption across the world. Moreover, increases antibiotics demand during transplants, dialysis, suppressed immune system, joint replacement, and others boosts the market growth.
Surge in demand for antibiotics, owing to increased consumption in low- & middle-income countries and rise in prevalence of infectious diseases are the key factors that boost the growth of the global antibiotics market. In addition, development of novel approaches for new antibiotics to treat bacterial infections and increase in clinical trials to determine safety & efficacy of the antibiotics drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics, and time taken for regulatory approval are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer lucrative opportunities for the market players.
The global antibiotics market is segmented based on class, drug origin, spectrum of activity, route of administration, and region. On the basis of class, the market is classified as beta lactam & beta lactamase inhibitors, macrolides, quinolones, and others. The beta lactam & beta lactamase inhibitors segment is further segmented into penicillin, cephalosporin, monobactam, and carbapenem. Depending on drug origin, the antibiotics market is categorized into natural, semisynthetic, and synthetic. According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. Based on route of administration, it is segregated into oral, intravenous, and others. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Antibiotics Market :
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global antibiotics market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
Antibiotics Key Market Segments :
By Class
Beta Lactam & Beta Lactamase Inhibitors
Penicillin
Cephalosporin
Carbapenem
Monobactam
Quinolones
Macrolides
Others
By Drug Origin
Natural
Semisynthetic
Synthetic
By Spectrum of Activity
Broad-spectrum Antibiotic
Narrow-spectrum Antibiotic
By Route of Administration
Oral
Intravenous
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
Spain
Italy
UK
Rest of Europe
Asia-Pacific
Australia
Japan
India
China
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
KEY MARKET PLAYERS
Abbott Laboratories
Allergan Plc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc.
Merck & Co. Inc.
Mylan N.V.
Novartis International AG (Sandoz)
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
The other players in the value chain include (profiles not included in the report):
Aurobindo Pharma
Bayer HealthCare
Eli Lilly
Lupin Pharmaceuticals
Sun Pharmaceutical
Shionogi
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3.1. Top winning strategies
3.4. Market share analysis, 2017
3.5. Porters five forces analysis
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Increased consumption in low and middle-income countries (LMICs)
3.6.1.2. Rising prevalence of infectious diseases
3.6.1.3. Development of novel approaches for new antibiotics for treating bacterial infections and a large number of clinical trials.
3.6.2. Restraints
3.6.2.1. Development of Antibiotic resistance, driven by misuse of antibiotics
3.6.2.2. The time taken for the regulatory approval
3.6.3. Opportunities
3.6.3.1. Discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections.
CHAPTER 4: ANTIBIOTICS MARKET, BY CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Beta Lactam and Beta Lactamase Inhibitors
4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Penicillins
4.2.2.1.1. Market size and forecast
4.2.2.2. Cephalosporins
4.2.2.2.1. Market size and forecast
4.2.2.3. Carbapenems
4.2.2.3.1. Market size and forecast
4.2.2.4. Monobactams
4.2.2.4.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. Quinolones
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Macrolides
4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends and growth opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5: ANTIBIOTICS MARKET, BY DRUG ORIGIN
5.1. Overview
5.1.1. Market size and forecast
5.2. Natural
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Semisynthetic
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Synthetic
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY
6.1. Overview
6.1.1. Market size and forecast
6.2. Broad-spectrum antibiotic
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Narrow-spectrum antibiotic
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
CHAPTER 7: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.1.1. Market size and forecast
7.2. Oral
7.2.1. Market size and forecast, by region
7.2.2. Market analysis, by country
7.3. Intravenous
7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country
7.4. Others
7.4.1. Market size and forecast, by region
7.4.2. Market analysis, by country
CHAPTER 8: ANTIBIOTICS MARKET, BY GEOGRAPHY
8.1. OVERVIEW
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends and opportunities
8.2.2. North America antibiotics market, by country
8.2.2.1. U.S. antibiotics market by class
8.2.2.2. U.S. antibiotics market by drug origin
8.2.2.3. U.S. antibiotics market by spectrum of activity
8.2.2.4. U.S. antibiotics market by Route of administration
8.2.2.5. Canada antibiotics market by class
8.2.2.6. Canada antibiotics market by drug origin
8.2.2.7. Canada antibiotics market by spectrum of activity
8.2.2.8. Canada antibiotics market by route of administration
8.2.2.9. Mexico antibiotics market by class
8.2.2.10. Mexico antibiotics market by drug origin
8.2.2.11. Mexico antibiotics market by spectrum of activity
8.2.2.12. Mexico antibiotics market by route of administration
8.2.3. North America antibiotics market, by class
8.2.4. North America antibiotics market, by drug origin
8.2.5. North America antibiotics market, by spectrum of activity
8.2.6. North America antibiotics market, by route of administration
8.3. Europe
8.3.1. Key market trends and opportunities
8.3.2. Europe antibiotics market, by country
8.3.2.1. Germany antibiotics market by class
8.3.2.2. Germany antibiotics market by drug origin
8.3.2.3. Germany antibiotics market by spectrum of activity
8.3.2.4. Germany antibiotics market by Route of administration
8.3.2.5. France antibiotics market by class
8.3.2.6. France antibiotics market by drug origin
8.3.2.7. France antibiotics market by spectrum of activity
8.3.2.8. France antibiotics market by route of administration
8.3.2.9. Spain antibiotics market by class
8.3.2.10. Spain antibiotics market by drug origin
8.3.2.11. Spain antibiotics market by spectrum of activity
8.3.2.12. Spain antibiotics market by route of administration
8.3.2.13. Italy antibiotics market by class
8.3.2.14. Italy antibiotics market by drug origin
8.3.2.15. Italy antibiotics market by spectrum of activity
8.3.2.16. Italy antibiotics market by route of administration
8.3.2.17. UK antibiotics market by class
8.3.2.18. UK antibiotics market by drug origin
8.3.2.19. UK antibiotics market by spectrum of activity
8.3.2.20. UK antibiotics market by route of administration
8.3.2.21. Rest of Europe antibiotics market by class
8.3.2.22. Rest of Europe antibiotics market by drug origin
8.3.2.23. Rest of Europe antibiotics market by spectrum of activity
8.3.2.24. Rest of Europe antibiotics market by route of administration
8.3.3. Europe antibiotics market, by class
8.3.4. Europe antibiotics market, by drug origin
8.3.5. Europe antibiotics market, by spectrum of activity
8.3.6. Europe antibiotics market, by route of administration
8.4. Asia-Pacific
8.4.1. Key market trends and opportunities
8.4.2. Asia-Pacific antibiotics market, by country
8.4.2.1. Australia antibiotics market by class
8.4.2.2. Australia antibiotics market by drug origin
8.4.2.3. Australia antibiotics market by spectrum of activity
8.4.2.4. Australia antibiotics market by Route of administration
8.4.2.5. Japan antibiotics market by class
8.4.2.6. Japan antibiotics market by drug origin
8.4.2.7. Japan antibiotics market by spectrum of activity
8.4.2.8. Japan antibiotics market by route of administration
8.4.2.9. India antibiotics market by class
8.4.2.10. India antibiotics market by drug origin
8.4.2.11. India antibiotics market by spectrum of activity
8.4.2.12. India antibiotics market by route of administration
8.4.2.13. China antibiotics market by class
8.4.2.14. China antibiotics market by drug origin
8.4.2.15. China antibiotics market by spectrum of activity
8.4.2.16. China antibiotics market by route of administration
8.4.2.17. Rest of Asia-Pacific antibiotics market by class
8.4.2.18. Rest of Asia-Pacific antibiotics market by drug origin
8.4.2.19. Rest of Asia-Pacific antibiotics market by spectrum of activity
8.4.2.20. Rest of Asia-Pacific antibiotics market by route of administration
8.4.3. Asia-Pacific antibiotics market, by class
8.4.4. Asia-Pacific antibiotics market, by drug origin
8.4.5. Asia-Pacific antibiotics market, by spectrum of activity
8.4.6. Asia-Pacific antibiotics market, by route of administration
8.5. LAMEA
8.5.1. Key market trends and opportunities
8.5.2. LAMEA antibiotics market, by country
8.5.2.1. Brazil antibiotics market by class
8.5.2.2. Brazil antibiotics market by drug origin
8.5.2.3. Brazil antibiotics market by spectrum of activity
8.5.2.4. Brazil antibiotics market by Route of administration
8.5.2.5. Saudi Arabia antibiotics market by class
8.5.2.6. Saudi Arabia antibiotics market by drug origin
8.5.2.7. Saudi Arabia antibiotics market by spectrum of activity
8.5.2.8. Saudi Arabia antibiotics market by route of administration
8.5.2.9. South Africa antibiotics market by class
8.5.2.10. South Africa antibiotics market by drug origin
8.5.2.11. South Africa antibiotics market by spectrum of activity
8.5.2.12. South Africa antibiotics market by route of administration
8.5.2.13. Rest of LAMEA antibiotics market by class
8.5.2.14. Rest of LAMEA antibiotics market by drug origin
8.5.2.15. Rest of LAMEA antibiotics market by spectrum of activity
8.5.2.16. Rest of LAMEA antibiotics market by route of administration
8.5.3. LAMEA antibiotics market, by class
8.5.4. LAMEA antibiotics market, by drug origin
8.5.5. LAMEA antibiotics market, by spectrum of activity
8.5.6. LAMEA antibiotics market, by route of administration
CHAPTER 9: COMPANY PROFILES
9.1. Abbott Laboratories
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.2. Allergan Plc.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance
9.2.6. Key strategic moves and developments
9.3. F. Hoffmann-La Roche Ltd.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments
9.4. GlaxoSmithKline plc
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.5. Merck & Co. Inc.
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments
9.6. Mylan N.V.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.6.6. Key strategic moves and developments
9.7. Novartis International AG (Sandoz)
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.8. Pfizer Inc.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments
9.9. Sanofi
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments
9.10. Teva Pharmaceutical Industries Ltd.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
